In vitro activities of tigecycline, ertapenem, isepamicin, and other antimicrobial agents against clinically isolated organisms in Taiwan

Nai Cheng Cheng, Po Ren Hsueh, Yung Ching Liu, Jainn Ming Shyr, Wen Kuei Huang, Lee Jene Teng, Cheng Yi Liu

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

This study evaluated the in vitro activities of tigecycline, ertapenem, isepamicin, and other comparators against 861 bacterial isolates recovered from patients treated in three major teaching hospitals in 2003. MICs to antimicrobial agents were determined by the agar dilution method. High rates of oxacillin resistance (58%) in Staphylococcus aureus (60 isolates), and vancomycin resistance (21%) and quinupristin-dalfopristin nonsusceptibility (39%) in Enterococcus faecium (34 isolates) were found. Carbapenems had excellent in vitro activities (≥98% susceptibility) against the 419 isolates of Enterobacteriaceae, with the MIC 50 and MIC 90 of imipenem, meropenem, and ertapenem being 0.25 and 4 mg/L, 0.03 and 0.12 mg/L, and 0.03 and 0.5 mg/L, respectively. For, Pseudomonas aeruginosa (74 isolates) and Burkholderia cepacia (21 isolates), meropenem (MIC 90, 0.25, 2, and 4 mg/L, respectively) had better in vitro activities than imipenem (MIC 90, 8, 4, and 32 mg/L, respectively) and ertapenem (MIC 90, 0.5, > 32, and 32 mg/L, respectively). Isepamicin had a similar activity with amikacin against all Enterobacteriaceae, Pseudomonas aeruginosa, B. cepacia, and Acinetobacter baumannii, except for C. freundii isolates in which isepamicin had an eight-fold activity better than amikacin. Tigecycline had excellent in vitro activities against all isolates tested (MIC 90, ≤1 mg/L) including 14 pandrug-resistant A. baumannii isolates (MICs, 1-4 mg/L), except for Proteus mirabilis (59 isolates; MIC 90, 8 mg/L), Bacteroides fragilis (60 isolates; MIC 90, 8 mg/L), P. aeruginosa (MIC 90,16 mg/L), and B. cepacia (21 isolates; MIC 90, 16 mg/L). Tigecycline, carbapenems, and isepamicin exhibited better or comparable in vitro activities against a wide spectrum of commonly encountered bacteria than other comparator antimicrobials and may represent therapeutic options for infections due to multidrug-resistant pathogens.

Original languageEnglish
Pages (from-to)330-341
Number of pages12
JournalMicrobial Drug Resistance
Volume11
Issue number4
DOIs
Publication statusPublished - Dec 2005
Externally publishedYes

Fingerprint

Anti-Infective Agents
Taiwan
meropenem
Burkholderia cepacia
Pseudomonas aeruginosa
Acinetobacter baumannii
Carbapenems
Amikacin
Imipenem
Enterobacteriaceae
Vancomycin Resistance
Oxacillin
Bacteroides fragilis
Enterococcus faecium
Proteus mirabilis
Teaching Hospitals
Agar
Staphylococcus aureus
tigecycline
isepamicin

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pharmacology
  • Immunology
  • Microbiology

Cite this

In vitro activities of tigecycline, ertapenem, isepamicin, and other antimicrobial agents against clinically isolated organisms in Taiwan. / Cheng, Nai Cheng; Hsueh, Po Ren; Liu, Yung Ching; Shyr, Jainn Ming; Huang, Wen Kuei; Teng, Lee Jene; Liu, Cheng Yi.

In: Microbial Drug Resistance, Vol. 11, No. 4, 12.2005, p. 330-341.

Research output: Contribution to journalArticle

Cheng, Nai Cheng ; Hsueh, Po Ren ; Liu, Yung Ching ; Shyr, Jainn Ming ; Huang, Wen Kuei ; Teng, Lee Jene ; Liu, Cheng Yi. / In vitro activities of tigecycline, ertapenem, isepamicin, and other antimicrobial agents against clinically isolated organisms in Taiwan. In: Microbial Drug Resistance. 2005 ; Vol. 11, No. 4. pp. 330-341.
@article{e04a3a91a59f449e95f131a9928ea59f,
title = "In vitro activities of tigecycline, ertapenem, isepamicin, and other antimicrobial agents against clinically isolated organisms in Taiwan",
abstract = "This study evaluated the in vitro activities of tigecycline, ertapenem, isepamicin, and other comparators against 861 bacterial isolates recovered from patients treated in three major teaching hospitals in 2003. MICs to antimicrobial agents were determined by the agar dilution method. High rates of oxacillin resistance (58{\%}) in Staphylococcus aureus (60 isolates), and vancomycin resistance (21{\%}) and quinupristin-dalfopristin nonsusceptibility (39{\%}) in Enterococcus faecium (34 isolates) were found. Carbapenems had excellent in vitro activities (≥98{\%} susceptibility) against the 419 isolates of Enterobacteriaceae, with the MIC 50 and MIC 90 of imipenem, meropenem, and ertapenem being 0.25 and 4 mg/L, 0.03 and 0.12 mg/L, and 0.03 and 0.5 mg/L, respectively. For, Pseudomonas aeruginosa (74 isolates) and Burkholderia cepacia (21 isolates), meropenem (MIC 90, 0.25, 2, and 4 mg/L, respectively) had better in vitro activities than imipenem (MIC 90, 8, 4, and 32 mg/L, respectively) and ertapenem (MIC 90, 0.5, > 32, and 32 mg/L, respectively). Isepamicin had a similar activity with amikacin against all Enterobacteriaceae, Pseudomonas aeruginosa, B. cepacia, and Acinetobacter baumannii, except for C. freundii isolates in which isepamicin had an eight-fold activity better than amikacin. Tigecycline had excellent in vitro activities against all isolates tested (MIC 90, ≤1 mg/L) including 14 pandrug-resistant A. baumannii isolates (MICs, 1-4 mg/L), except for Proteus mirabilis (59 isolates; MIC 90, 8 mg/L), Bacteroides fragilis (60 isolates; MIC 90, 8 mg/L), P. aeruginosa (MIC 90,16 mg/L), and B. cepacia (21 isolates; MIC 90, 16 mg/L). Tigecycline, carbapenems, and isepamicin exhibited better or comparable in vitro activities against a wide spectrum of commonly encountered bacteria than other comparator antimicrobials and may represent therapeutic options for infections due to multidrug-resistant pathogens.",
author = "Cheng, {Nai Cheng} and Hsueh, {Po Ren} and Liu, {Yung Ching} and Shyr, {Jainn Ming} and Huang, {Wen Kuei} and Teng, {Lee Jene} and Liu, {Cheng Yi}",
year = "2005",
month = "12",
doi = "10.1089/mdr.2005.11.330",
language = "English",
volume = "11",
pages = "330--341",
journal = "Microbial Drug Resistance",
issn = "1076-6294",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - In vitro activities of tigecycline, ertapenem, isepamicin, and other antimicrobial agents against clinically isolated organisms in Taiwan

AU - Cheng, Nai Cheng

AU - Hsueh, Po Ren

AU - Liu, Yung Ching

AU - Shyr, Jainn Ming

AU - Huang, Wen Kuei

AU - Teng, Lee Jene

AU - Liu, Cheng Yi

PY - 2005/12

Y1 - 2005/12

N2 - This study evaluated the in vitro activities of tigecycline, ertapenem, isepamicin, and other comparators against 861 bacterial isolates recovered from patients treated in three major teaching hospitals in 2003. MICs to antimicrobial agents were determined by the agar dilution method. High rates of oxacillin resistance (58%) in Staphylococcus aureus (60 isolates), and vancomycin resistance (21%) and quinupristin-dalfopristin nonsusceptibility (39%) in Enterococcus faecium (34 isolates) were found. Carbapenems had excellent in vitro activities (≥98% susceptibility) against the 419 isolates of Enterobacteriaceae, with the MIC 50 and MIC 90 of imipenem, meropenem, and ertapenem being 0.25 and 4 mg/L, 0.03 and 0.12 mg/L, and 0.03 and 0.5 mg/L, respectively. For, Pseudomonas aeruginosa (74 isolates) and Burkholderia cepacia (21 isolates), meropenem (MIC 90, 0.25, 2, and 4 mg/L, respectively) had better in vitro activities than imipenem (MIC 90, 8, 4, and 32 mg/L, respectively) and ertapenem (MIC 90, 0.5, > 32, and 32 mg/L, respectively). Isepamicin had a similar activity with amikacin against all Enterobacteriaceae, Pseudomonas aeruginosa, B. cepacia, and Acinetobacter baumannii, except for C. freundii isolates in which isepamicin had an eight-fold activity better than amikacin. Tigecycline had excellent in vitro activities against all isolates tested (MIC 90, ≤1 mg/L) including 14 pandrug-resistant A. baumannii isolates (MICs, 1-4 mg/L), except for Proteus mirabilis (59 isolates; MIC 90, 8 mg/L), Bacteroides fragilis (60 isolates; MIC 90, 8 mg/L), P. aeruginosa (MIC 90,16 mg/L), and B. cepacia (21 isolates; MIC 90, 16 mg/L). Tigecycline, carbapenems, and isepamicin exhibited better or comparable in vitro activities against a wide spectrum of commonly encountered bacteria than other comparator antimicrobials and may represent therapeutic options for infections due to multidrug-resistant pathogens.

AB - This study evaluated the in vitro activities of tigecycline, ertapenem, isepamicin, and other comparators against 861 bacterial isolates recovered from patients treated in three major teaching hospitals in 2003. MICs to antimicrobial agents were determined by the agar dilution method. High rates of oxacillin resistance (58%) in Staphylococcus aureus (60 isolates), and vancomycin resistance (21%) and quinupristin-dalfopristin nonsusceptibility (39%) in Enterococcus faecium (34 isolates) were found. Carbapenems had excellent in vitro activities (≥98% susceptibility) against the 419 isolates of Enterobacteriaceae, with the MIC 50 and MIC 90 of imipenem, meropenem, and ertapenem being 0.25 and 4 mg/L, 0.03 and 0.12 mg/L, and 0.03 and 0.5 mg/L, respectively. For, Pseudomonas aeruginosa (74 isolates) and Burkholderia cepacia (21 isolates), meropenem (MIC 90, 0.25, 2, and 4 mg/L, respectively) had better in vitro activities than imipenem (MIC 90, 8, 4, and 32 mg/L, respectively) and ertapenem (MIC 90, 0.5, > 32, and 32 mg/L, respectively). Isepamicin had a similar activity with amikacin against all Enterobacteriaceae, Pseudomonas aeruginosa, B. cepacia, and Acinetobacter baumannii, except for C. freundii isolates in which isepamicin had an eight-fold activity better than amikacin. Tigecycline had excellent in vitro activities against all isolates tested (MIC 90, ≤1 mg/L) including 14 pandrug-resistant A. baumannii isolates (MICs, 1-4 mg/L), except for Proteus mirabilis (59 isolates; MIC 90, 8 mg/L), Bacteroides fragilis (60 isolates; MIC 90, 8 mg/L), P. aeruginosa (MIC 90,16 mg/L), and B. cepacia (21 isolates; MIC 90, 16 mg/L). Tigecycline, carbapenems, and isepamicin exhibited better or comparable in vitro activities against a wide spectrum of commonly encountered bacteria than other comparator antimicrobials and may represent therapeutic options for infections due to multidrug-resistant pathogens.

UR - http://www.scopus.com/inward/record.url?scp=30744457825&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30744457825&partnerID=8YFLogxK

U2 - 10.1089/mdr.2005.11.330

DO - 10.1089/mdr.2005.11.330

M3 - Article

C2 - 16359192

AN - SCOPUS:30744457825

VL - 11

SP - 330

EP - 341

JO - Microbial Drug Resistance

JF - Microbial Drug Resistance

SN - 1076-6294

IS - 4

ER -